SEARCH

SEARCH BY CITATION

References

  • 1
    Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: results of the massachusetts male aging study. J Urol 1994; 151: 5461.
  • 2
    Jensen J, Lendorf A, Stimpel H, Frost J, Ibsen H, Rosenkilde P. The prevalence and etiology of impotence in 101 male hypertensive outpatients. Am J Hypertens 1999; 12: 271275.
  • 3
    Saenz De Tejada I, Goldstein I, Azadzoi K, Krane RJ, Cohen RA. Impaired neurogenic and endothelium-mediated relaxation of penile smooth muscle from diabetic men with impotence. N Engl J Med 1989; 320: 10251030.
  • 4
    Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA. Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. N Engl J Med 1998; 338: 13971404.
  • 5
    Chew KK. Prevalence of erectile dysfunction in community-based studies. Int J Impot Res 2004; 16: 201202.
  • 6
    Kirby M, Jackson G, Betteridge J, Friedli K. Is erectile dysfunction a marker for cardiovascular disease? Int J Clin Pract 2001; 55: 614618.
  • 7
    Fedele D, Coscelli C, Santeusanio F, Bortolotti A, Chatenoud L, Colli E et al. Erectile dysfunction in diabetic subjects in Italy. Gruppo Italiano Studio Deficit Erettile nei Diabetici. Diabetes Care 1998; 21: 19731977.
  • 8
    De Berardis G, Pellegrini F, Franciosi M, Belfiglio M, Di Nardo B, Greenfield S et al. Identifying patients with type 2 diabetes with a higher likelihood of erectile dysfunction: the role of the interaction between clinical and psychological factors. J Urol 2003; 169: 14221428.
  • 9
    Brunner GA, Pieber TR, Schattenberg S, Ressi G, Wieselmann G, Altziebler S et al. [Erectile dysfunction in patients with type I diabetes mellitus]. Wien Med Wochenschr 1995; 145: 584586.
  • 10
    Rosen R, Altwein J, Boyle P, Kirby RS, Lukacs B, Meuleman E et al. Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). Eur Urol 2003; 44: 637649.
  • 11
    Cappelleri JC, Rosen RC, Smith MD, Mishra A, Osterloh IH. Diagnostic evaluation of the erectile function domain of the international index of erectile function. Urology 1999; 54: 346351.
  • 12
    Althof SE. Quality of life and erectile dysfunction. Urology 2002; 59: 803810.
  • 13
    Seidman SN, Roose SP, Menza MA, Shabsigh R, Rosen RC. Treatment of erectile dysfunction in men with depressive symptoms: results of a placebo-controlled trial with sildenafil citrate. Am J Psychiatry 2001; 158: 16231630.
  • 14
    Jackson G, Rosen RC, Kloner RA, Kostis HB. The second princeton consensus on sexual dysfunction and cardiac risk: new guidelines for sexual medicine. J Sex Med 2006; 3: 2836; discussion 36.
  • 15
    Melnik T, Althof S, Atallah AN, Puga ME, Glina S, Riera R. Psychosocial interventions for premature ejaculation. Cochrane Database Syst Rev 2011; CD008195.
  • 16
    Hawton K, Catalan J, Martin P, Fagg J. Long-term outcome of sex therapy. Behav Res Ther 1986; 24: 665675.
  • 17
    Porst H, Rosen R, Padma-Nathan H, Goldstein I, Giuliano F, Ulbrich E et al. The efficacy and tolerability of vardenafil, a new, oral, selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction: the first at-home clinical trial. Int J Impot Res 2001; 13: 192199.
  • 18
    Brock GB, McMahon CG, Chen KK, Costigan T, Shen W, Watkins V et al. Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses. J Urol 2002; 168 (4 Pt 1): 13321336.
  • 19
    Porst H, Giuliano F, Glina S, Ralph R, Adolfo R, Casabe AR et al. Evaluation of the efficacy and safety of once-a-day dosing of tadalafil 5 mg and 10 mg in the treatment of erectile dysfunction: results of a multicenter, randomized, double-blind, placebo-controlled trial. Eur Urol 2006; 50: 351359.
  • 20
    McMahon C. Efficacy and safety of daily tadalafil in men with erectile dysfunction previously unresponsive to on-demand tadalafil. J Sex Med 2004; 1: 292300.
  • 21
    Porst H. The rationale for prostaglandin E1 in erectile failure: a survey of worldwide experience. J Urol 1996; 55: 802815.
  • 22
    McMahon CG. Comparison of the response to the intracavernosal injection of a combination of papaverine and phentolamine, prostaglandin E1 alone and a combination of all three in the management of impotence. Int J Impotence Res 1991; 3: 133142.
  • 23
    Pryor J, Akkus E, Alter G, Jordan G, Lebret T, Levine L et al. Peyronie's disease. J Sex Med 2004; 1: 110115.